Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreements with Arcus Biosciences, Inc and Bristol-Myers Squibb Company.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-453-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.15 million
Profitability
Miscellaneous
Employees25
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable
Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions
What is Infinity Pharmaceuticals' stock symbol?
Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."
How were Infinity Pharmaceuticals' earnings last quarter?
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) released its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.02. The biotechnology company earned $0.34 million during the quarter, compared to analysts' expectations of $0.85 million. Infinity Pharmaceuticals had a negative net margin of 1,519.91% and a negative return on equity of 125.37%. View Infinity Pharmaceuticals' Earnings History.
When is Infinity Pharmaceuticals' next earnings date?
What price target have analysts set for INFI?
3 brokers have issued 1-year price objectives for Infinity Pharmaceuticals' stock. Their forecasts range from $3.00 to $3.50. On average, they anticipate Infinity Pharmaceuticals' stock price to reach $3.25 in the next twelve months. This suggests a possible upside of 124.1% from the stock's current price. View Analyst Price Targets for Infinity Pharmaceuticals.
What is the consensus analysts' recommendation for Infinity Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Infinity Pharmaceuticals.
Has Infinity Pharmaceuticals been receiving favorable news coverage?
News stories about INFI stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Infinity Pharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Infinity Pharmaceuticals.
Are investors shorting Infinity Pharmaceuticals?
Infinity Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 124,500 shares, an increase of 79.7% from the January 15th total of 69,300 shares. Based on an average daily volume of 149,300 shares, the short-interest ratio is currently 0.8 days. Approximately 0.2% of the shares of the company are sold short. View Infinity Pharmaceuticals' Current Options Chain.
Who are some of Infinity Pharmaceuticals' key competitors?
Some companies that are related to Infinity Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).
What other stocks do shareholders of Infinity Pharmaceuticals own?
Who are Infinity Pharmaceuticals' key executives?
Infinity Pharmaceuticals' management team includes the folowing people:
- Ms. Adelene Q. Perkins, Chairman & CEO (Age 59)
- Dr. Lawrence E. Bloch, Pres & Treasurer (Age 53)
- Dr. Jeffery L. Kutok, Sr. VP & Chief Scientific Officer (Age 52)
- Mr. Seth A. Tasker, VP, Gen. Counsel & Sec. (Age 40)
- Ms. Melissa Hackel, VP of Fin.
Who are Infinity Pharmaceuticals' major shareholders?
Infinity Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.21%), Acadian Asset Management LLC (1.11%), Oxford Asset Management LLP (0.38%), Jacobs Levy Equity Management Inc. (0.24%) and Virtu Financial LLC (0.05%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Bvf Partners L P/Il, Jeffery Kutok and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.
Which major investors are selling Infinity Pharmaceuticals stock?
Which major investors are buying Infinity Pharmaceuticals stock?
INFI stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Virtu Financial LLC and Acadian Asset Management LLC. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Infinity Pharmaceuticals.
How do I buy shares of Infinity Pharmaceuticals?
Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Infinity Pharmaceuticals' stock price today?
One share of INFI stock can currently be purchased for approximately $1.45.
How big of a company is Infinity Pharmaceuticals?
Infinity Pharmaceuticals has a market capitalization of $82.69 million and generates $22.15 million in revenue each year. The biotechnology company earns $-11,250,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis. Infinity Pharmaceuticals employs 25 workers across the globe.View Additional Information About Infinity Pharmaceuticals.
What is Infinity Pharmaceuticals' official website?
How can I contact Infinity Pharmaceuticals?
Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]
MarketBeat Community Rating for Infinity Pharmaceuticals (NASDAQ INFI)
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe INFI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days.
